Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which therapeutic option for hepatitis C virus genotype 1?

Scandinavian journal of gastroenterology - 1 Apr 2015

Brochot Etienne, Helle François, François Catherine, Castelain Sandrine, Capron Dominique, Nguyen-Khac Eric, Duverlie Gilles

Abstract excerpt

OBJECTIVE: Sofosbuvir and simeprevir in combination with standard therapy are now available for the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1. With boceprevir and telaprevir, four treatment options are, therefore, now available to clinicians. Phase 3 studies conducted with simeprevir and sofosbuvir compared sustained virological response (SVR) data with those obtained with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to Interferons

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interleukins

Share to Oligopeptides

Share to Proline

Share to Randomized Controlled Trials as Topic

Share to Simeprevir

Share to Sofosbuvir

Source

Identifiers

PMID: 25396710
DOI: 10.3109/00365521.2014.978364

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which therapeutic option for hepatitis C virus genotype 1?PMID 25396710Read ↗

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.Semantic proximity Read ↗

Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.Semantic proximity Read ↗

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.Semantic proximity Read ↗

Simeprevir for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.Semantic proximity Read ↗

Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.Semantic proximity Read ↗

Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach.Semantic proximity Read ↗

Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.Semantic proximity Read ↗

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.Semantic proximity Read ↗

Approach to the treatment-naïve patient with HCV genotype 1 infection.Semantic proximity Read ↗

Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.